H.C. Wainwright Sticks to Their Buy Rating for Taiwan Liposome Company Ltd (TLC)

By Jason Carr

H.C. Wainwright analyst Oren Livnat maintained a Buy rating on Taiwan Liposome Company Ltd (TLCResearch Report) today and set a price target of $10.00. The company’s shares closed last Monday at $5.25, close to its 52-week low of $4.96.

According to TipRanks.com, Livnat is a 4-star analyst with an average return of 7.8% and a 49.3% success rate. Livnat covers the Healthcare sector, focusing on stocks such as Verrica Pharmaceuticals Inc, Collegium Pharmaceutical, and Zynerba Pharmaceuticals.

Currently, the analyst consensus on Taiwan Liposome Company Ltd is a Moderate Buy with an average price target of $10.00.

See today’s analyst top recommended stocks >>

The company has a one-year high of $11.00 and a one-year low of $4.96. Currently, Taiwan Liposome Company Ltd has an average volume of 887.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

Taiwan Liposome Co., Ltd. engages in the authorized cooperative development of special medicine as well as new formulation and prescription drugs. Its products include pain management, ophthalmology, and oncology related drugs based on lipid drug delivery system. It also provides royalties and biotechnology services.